Muraki A
Department of Psychiatry and Neurology, Hokkaido University School of Medicine, Sapporo, Japan.
Hokkaido Igaku Zasshi. 1993 May;68(3):407-18.
In humans, repeated use of methamphetamine produces hypersensitivity to the psychotogenic effects of methamphetamine that persists for months to years after the discontinuation of methamphetamine administration. Methamphetamine-induced psychosis has been thought to be a useful experimental model for schizophrenia. A possible involvement of the glutamate system in the hypersensitivity including behavioral sensitization or reverse tolerance is recognized in an animal model for methamphetamine psychosis. We investigated the effects of antagonists of N-methyl-D-aspartate (NMDA) receptor on methamphetamine-induced decrease in dopamine (DA) uptake sites in the rat striatum and on the behavioral sensitization. Repeated administrations of escalating doses of methamphetamine (2.5, 5, 7.5, 10mg/kg s. c. x 2, every other day for a week) decreased DA uptake sites to about 75% of the control in the striatum assayed by binding with [3H]GBR 12935. Co-administration of MK-801, a non-competitive antagonist of NMDA receptor, and methamphetamine significantly prevented the methamphetamine-induced decrease in striatal [3H]GBR 12935 binding in a dose dependent manner. Administration of MK-801 alone did not affect the [3H]GBR 12935 binding. Furthermore, co-administration of SDZ EAA494, a competitive antagonist of NMDA receptor, and methamphetamine also prevented the methamphetamine-induced decrease in the striatal [3H]GBR 12935 binding in a dose dependent manner. In methamphetamine-pretreated rats, the methamphetamine challenge (2.5mg/kg) after a 7-day-drug-free period produced an initial elevation in locomotion lasting for 10-30 min which was followed by a precipitous drop in the locomotion activity to very low levels for approximately 50-70 min. During the period of reduced locomotor activity, methamphetamine-pretreated rats showed intense focused stereotyped behavior. In contrast, animals treated with both MK-801 and methamphetamine showed neither the progressive enhancement of the locomotor activity nor the stereotyped behavior induced by the drug. Pretreatment with MK-801 blocked the development of the methamphetamine-induced behavioral sensitization. These results suggest an involvement of excitatory amino acids in neurochemical effects of methamphetamine on the dopamine system in the striatum.
在人类中,反复使用甲基苯丙胺会导致对甲基苯丙胺致幻作用产生超敏反应,这种超敏反应在停止使用甲基苯丙胺后的数月至数年里持续存在。甲基苯丙胺诱发的精神病被认为是精神分裂症的一种有用的实验模型。在甲基苯丙胺精神病的动物模型中,人们认识到谷氨酸系统可能参与了包括行为敏化或反向耐受在内的超敏反应。我们研究了N-甲基-D-天冬氨酸(NMDA)受体拮抗剂对甲基苯丙胺诱导的大鼠纹状体中多巴胺(DA)摄取位点减少以及行为敏化的影响。通过与[3H]GBR 12935结合测定,反复给予递增剂量的甲基苯丙胺(2.5、5、7.5、10mg/kg,皮下注射,每周隔日注射2次,共一周)使纹状体中的DA摄取位点减少至对照组的约75%。NMDA受体的非竞争性拮抗剂MK-801与甲基苯丙胺共同给药,能以剂量依赖的方式显著阻止甲基苯丙胺诱导的纹状体中[3H]GBR 12935结合减少。单独给予MK-801不影响[3H]GBR 12935结合。此外,NMDA受体的竞争性拮抗剂SDZ EAA494与甲基苯丙胺共同给药,也能以剂量依赖的方式阻止甲基苯丙胺诱导的纹状体中[3H]GBR 12935结合减少。在经甲基苯丙胺预处理的大鼠中,在停药7天后给予甲基苯丙胺激发剂量(2.5mg/kg),最初会使运动活动升高持续10 - 30分钟,随后运动活动急剧下降至极低水平,持续约50 - 70分钟。在运动活动降低期间,经甲基苯丙胺预处理的大鼠表现出强烈的集中刻板行为。相比之下,同时用MK-801和甲基苯丙胺处理的动物既没有表现出运动活动的渐进增强,也没有表现出药物诱导的刻板行为。用MK-801预处理可阻止甲基苯丙胺诱导的行为敏化的发展。这些结果表明兴奋性氨基酸参与了甲基苯丙胺对纹状体中多巴胺系统的神经化学作用。